Aqueous suspension containing budesonide for the treatment of inflammatory changes to the oesophagus
CN104394691A
Compositions and methods for treatment of irritable bowel syndrome with 5-aminosalicylate
EP2468762A1
Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
HK1136190A1
Pharmaceutical formulation for treating the upper digestive tract
EP2123774A1
Method for characterising the biological activity of Helminth eggs
EP1977643A1
Manufacture of a viable, storable worm egg suspension
EP1312368A1
Composition comprising mesalazine for the treatment of inflammatory bowel diseases
DE10058771A1
Coacervation process for the production of delayed-release drugs
DE10058772A1
Process for the preparation of readily soluble pharmaceutical formulations and corresponding formulations
DE19906290A1
Orally administered medicament for treating colon cancer comprises ursodesoxycholic acid in gastric fluid resistant coating to provide direct topical action at target site
DE19850445A1
Medicines for the topical treatment of inflammatory bowel disease
DE19849737A1
Combination agent for the treatment of inflammatory bowel disease
BR9806250A
Busesonde isolated or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases.
CA2216887A1
Budesonide alone or in combination with ursodeoxycholic acid in the therapy of cholestatic liver diseases
DE19742612A1
Budesonide for the treatment of cholestatic liver diseases
DE19732903A1
Pellet formulation for the treatment of the intestinal tract
DE19645044A1
Use of ursodeoxycholic acid for the topical treatment of inflammatory diseases of the mucous membranes
DE19631122A1
Use of ursodeoxycholic acid in HIV infection
DE4446891A1
Stable aqueous budesonide solution
DE4443377A1
Process for the preparation of isoursodeoxycholic acid
